‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
23 Oct 2026, 01:15 PM

‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows

G
Guard News
@guardnews
Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised wayGet our new political email, free app or daily news podcastA personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show.The vaccine, intismeran, is custom-made to target genetic mutations unique to an individual’s melanoma. It is the first individualised cancer vaccine to show positive results in a phase III clinical trial. Continue reading...
Source Credit: theguardian.com
Read Full Story
2

Comments (0)

Login to join the conversation
More News
More News
Presenter battles strong winds as Storm Austen hits Newquay
23 Oct 2026
Can AI really predict cancer survival better than a doctor? I have my doubts | Devi Sridhar
23 Oct 2026
Week in wildlife: a bookworm bear, an angelic spider and a bald hedgehog
23 Oct 2026
India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’
23 Oct 2026
Country diary: Slugs? Dull? This one is pure showbiz | Charlie Elder
23 Oct 2026
At Cop17, the pressure is on to rescue a deal that could end the destruction of nature
23 Oct 2026